vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Shutterstock, Inc. (SSTK). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $220.2M, roughly 1.3× Shutterstock, Inc.). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs -7.3%, a 103.6% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs -12.0%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 1.4%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Shutterstock, Inc. is an American provider of stock photography, stock footage, stock music, and editing tools; it is headquartered in New York. Founded in 2002 by programmer and photographer Jon Oringer, Shutterstock maintains a library of around 200 million royalty-free stock photos, vector graphics, and illustrations, with around 10 million video clips and music tracks available for licensing. Originally a subscription site only, Shutterstock expanded beyond subscriptions into à la carte p...
ACAD vs SSTK — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $220.2M |
| Net Profit | $273.6M | $-16.0M |
| Gross Margin | 90.8% | 55.8% |
| Operating Margin | 6.1% | -1.1% |
| Net Margin | 96.3% | -7.3% |
| Revenue YoY | 9.4% | -12.0% |
| Net Profit YoY | 90.3% | -1021.0% |
| EPS (diluted) | $1.61 | $-0.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $220.2M | ||
| Q3 25 | $278.6M | $260.1M | ||
| Q2 25 | $264.6M | $267.0M | ||
| Q1 25 | $244.3M | $242.6M | ||
| Q4 24 | $259.6M | $250.3M | ||
| Q3 24 | $250.4M | $250.6M | ||
| Q2 24 | $242.0M | $220.1M | ||
| Q1 24 | $205.8M | $214.3M |
| Q4 25 | $273.6M | $-16.0M | ||
| Q3 25 | $71.8M | $13.4M | ||
| Q2 25 | $26.7M | $29.4M | ||
| Q1 25 | $19.0M | $18.7M | ||
| Q4 24 | $143.7M | $-1.4M | ||
| Q3 24 | $32.8M | $17.6M | ||
| Q2 24 | $33.4M | $3.6M | ||
| Q1 24 | $16.6M | $16.1M |
| Q4 25 | 90.8% | 55.8% | ||
| Q3 25 | 92.2% | 60.6% | ||
| Q2 25 | 92.2% | 60.3% | ||
| Q1 25 | 91.7% | 58.4% | ||
| Q4 24 | 91.6% | 55.1% | ||
| Q3 24 | 92.5% | 58.3% | ||
| Q2 24 | 92.5% | 58.5% | ||
| Q1 24 | 88.8% | 58.8% |
| Q4 25 | 6.1% | -1.1% | ||
| Q3 25 | 12.8% | 12.5% | ||
| Q2 25 | 12.2% | 13.0% | ||
| Q1 25 | 7.9% | 4.2% | ||
| Q4 24 | 59.1% | 5.3% | ||
| Q3 24 | 12.6% | 7.2% | ||
| Q2 24 | 12.6% | 9.4% | ||
| Q1 24 | 7.4% | 7.8% |
| Q4 25 | 96.3% | -7.3% | ||
| Q3 25 | 25.8% | 5.1% | ||
| Q2 25 | 10.1% | 11.0% | ||
| Q1 25 | 7.8% | 7.7% | ||
| Q4 24 | 55.4% | -0.6% | ||
| Q3 24 | 13.1% | 7.0% | ||
| Q2 24 | 13.8% | 1.6% | ||
| Q1 24 | 8.0% | 7.5% |
| Q4 25 | $1.61 | $-0.47 | ||
| Q3 25 | $0.42 | $0.37 | ||
| Q2 25 | $0.16 | $0.82 | ||
| Q1 25 | $0.11 | $0.53 | ||
| Q4 24 | $0.86 | $-0.04 | ||
| Q3 24 | $0.20 | $0.50 | ||
| Q2 24 | $0.20 | $0.10 | ||
| Q1 24 | $0.10 | $0.45 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $178.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $581.0M |
| Total Assets | $1.6B | $1.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $178.2M | ||
| Q3 25 | $258.0M | $165.5M | ||
| Q2 25 | $253.6M | $116.4M | ||
| Q1 25 | $217.7M | $112.2M | ||
| Q4 24 | $319.6M | $111.3M | ||
| Q3 24 | $155.1M | $131.4M | ||
| Q2 24 | $177.1M | $74.9M | ||
| Q1 24 | $204.7M | $71.8M |
| Q4 25 | $1.2B | $581.0M | ||
| Q3 25 | $917.3M | $594.4M | ||
| Q2 25 | $822.4M | $586.2M | ||
| Q1 25 | $765.2M | $547.2M | ||
| Q4 24 | $732.8M | $518.4M | ||
| Q3 24 | $577.2M | $522.9M | ||
| Q2 24 | $516.7M | $520.4M | ||
| Q1 24 | $464.0M | $541.3M |
| Q4 25 | $1.6B | $1.4B | ||
| Q3 25 | $1.3B | $1.4B | ||
| Q2 25 | $1.2B | $1.4B | ||
| Q1 25 | $1.1B | $1.3B | ||
| Q4 24 | $1.2B | $1.3B | ||
| Q3 24 | $976.9M | $1.3B | ||
| Q2 24 | $914.1M | $1.0B | ||
| Q1 24 | $855.1M | $1.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $36.2M |
| Free Cash FlowOCF − Capex | — | $25.9M |
| FCF MarginFCF / Revenue | — | 11.8% |
| Capex IntensityCapex / Revenue | — | 4.7% |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $123.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $36.2M | ||
| Q3 25 | $74.3M | $78.4M | ||
| Q2 25 | $64.0M | $26.8M | ||
| Q1 25 | $20.3M | $25.2M | ||
| Q4 24 | $40.4M | $8.0M | ||
| Q3 24 | $63.2M | $-11.6M | ||
| Q2 24 | $25.0M | $28.0M | ||
| Q1 24 | $29.1M | $8.3M |
| Q4 25 | — | $25.9M | ||
| Q3 25 | $73.9M | $68.0M | ||
| Q2 25 | — | $15.5M | ||
| Q1 25 | — | $14.4M | ||
| Q4 24 | — | $-952.0K | ||
| Q3 24 | $63.2M | $-26.3M | ||
| Q2 24 | — | $18.9M | ||
| Q1 24 | — | $-6.2M |
| Q4 25 | — | 11.8% | ||
| Q3 25 | 26.5% | 26.1% | ||
| Q2 25 | — | 5.8% | ||
| Q1 25 | — | 6.0% | ||
| Q4 24 | — | -0.4% | ||
| Q3 24 | 25.2% | -10.5% | ||
| Q2 24 | — | 8.6% | ||
| Q1 24 | — | -2.9% |
| Q4 25 | — | 4.7% | ||
| Q3 25 | 0.1% | 4.0% | ||
| Q2 25 | — | 4.2% | ||
| Q1 25 | — | 4.5% | ||
| Q4 24 | — | 3.6% | ||
| Q3 24 | 0.0% | 5.9% | ||
| Q2 24 | — | 4.1% | ||
| Q1 24 | — | 6.7% |
| Q4 25 | -0.18× | — | ||
| Q3 25 | 1.03× | 5.86× | ||
| Q2 25 | 2.40× | 0.91× | ||
| Q1 25 | 1.07× | 1.35× | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | -0.66× | ||
| Q2 24 | 0.75× | 7.71× | ||
| Q1 24 | 1.76× | 0.51× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
SSTK
Segment breakdown not available.
